Today’s Stock Market in 2-Minutes
August 4, 2026
August 4, 2026
August 4, 2026
August 4, 2026
August 4, 2026
Patrick Gruber, CEO of Gevo (NASDAQ: GEVO), shares how the company is pioneering renewable, drop-in hydrocarbon jet fuels that are cost-competitive with traditional petroleum-based alternatives. With over 450 patents and projects backed by a $1.63B DOE loan guarantee, Gevo is scaling commercial production through facilities in South Dakota and North Dakota. The company’s ethanol-based jet fuel, carbon capture, and RNG assets are unlocking significant revenue streams—positioning Gevo to become EBITDA positive in 2025. With $270M+ in cash, strategic partnerships, and bipartisan support for 45Z tax credits, Gevo is accelerating the transition to net-zero aviation fuels.
May 22, 2025Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), […]
August 3, 2026
Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a non-binding Letter of Intent (“LOI”) to […]
August 3, 2026
NORTH PALM BEACH, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) — SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that its portfolio company Smartkem, Inc. (NASDAQ: SMTK), a leader in advanced materials, will merge […]
August 3, 2026
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the ESMO Gynaecological Cancers Congress 2026, reinforcing the biological and clinical rationale for evaluating COM701 in platinum-sensitive ovarian cancer Partner AstraZeneca presented new data at ASCO 2026, including the first […]
August 3, 2026
August 4, 2026
August 4, 2026
August 4, 2026
August 4, 2026
August 4, 2026
August 4, 2026
August 4, 2026
August 4, 2026